Can We Define the Ideal Duration of Antibiotic Therapy?

University of Virginia Surgical Infectious Disease Laboratory, Charlottesville, VA 22908, USA.
Surgical Infections (Impact Factor: 1.45). 10/2006; 7(5):419-32. DOI: 10.1089/sur.2006.7.419
Source: PubMed


Because of the increasing development of antimicrobial resistance, there is a greater responsibility within the medical community to limit the exposure of patients to antibiotics. We tested the hypothesis that shorter courses of antibiotics are associated with similar or better results than longer durations. We also sought to investigate the difference between a fixed duration of therapy and one based on physiologic measures such as fever and leukocytosis.
All infectious episodes on the general surgery units of the University of Virginia Health System from December 15, 1996, to July 31, 2003, were analyzed retrospectively for the relation between the duration of antibiotic therapy and infectious complications (recurrent infection with the same organism or at the same site). All infections associated with either fever or leukocytosis were categorized into quartiles on the basis of the absolute length of antibiotic administration or the duration of treatment following resolution of fever or leukocytosis. Multivariate logistic regression models were developed to estimate the independent risk of recurrence associated with a longer duration of antibiotic use.
Of the 5,561 treated infections, 4,470 were associated with fever (temperature > or =38 degrees C) or leukocytosis (white blood cell count > or =11,000/mm(3)). For all infections, whether analyzed by absolute duration or time from resolution of leukocytosis or fever, the first or second quartiles (0-12 days, 0-9 days, 0-9 days, respectively) were associated with the lowest recurrence rates (14-18%, 17-23%, 18-19%, respectively). Individual analysis of intra-abdominal infections and pneumonia yielded similar results. The fixed-duration groups received fewer days of antibiotics on average, with outcomes similar to those in the physiologic parameters group.
Shorter courses of antibiotics were associated with similar or fewer complications than prolonged therapy. In general, adopting a strategy of a fixed duration of therapy, rather than basing duration on resolution of fever or leukocytosis, appeared to yield similar outcomes with less antibiotic use.

Download full-text


Available from: Heather L Evans, Sep 09, 2014
  • Source
    • "The available trials randomly assigning patients with intra-abdominal infections to shorter versus longer durations of antibiotic therapy were conducted in non-ICU settings and populations and explicitly excluded those with generalized secondary peritonitis or nosocomial infections. Equivalent outcomes for shorter- versus longer-duration therapy for SBP and localized intra-abdominal infection are in keeping with similar findings in a retrospective analysis of 929 patients with intra-abdominal infections, in which less than 7 days of therapy was not associated with higher complications or mortality [53]. We have not uncovered evidence, though, of whether the effectiveness of short-duration therapy extends to patients with severe infections complicated by bacteremia or in those for whom source control cannot readily be achieved. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The optimal duration of antibiotic therapy for bloodstream infections is unknown. Shorter durations of therapy have been demonstrated to be as effective as longer durations for many common infections; similar findings in bacteremia could enable hospitals to reduce antibiotic utilization, adverse events, resistance and costs. A search of the MEDLINE, EMBASE and COCHRANE databases was conducted for the years 1947-2010. Controlled trials were identified that randomized patients to shorter versus longer durations of treatment for bacteremia, or the infectious foci most commonly causing bacteremia in critically ill patients (catheter-related bloodstream infections (CRBSI), intra-abdominal infections, pneumonia, pyelonephritis and skin and soft-tissue infections (SSTI)). Twenty-four eligible trials were identified, including one trial focusing exclusively on bacteremia, zero in catheter related bloodstream infection, three in intra-abdominal infection, six in pyelonephritis, thirteen in pneumonia and one in skin and soft tissue infection. Thirteen studies reported on 227 patients with bacteremia allocated to 'shorter' or 'longer' durations of treatment. Outcome data were available for 155 bacteremic patients: neonatal bacteremia (n = 66); intra-abdominal infection (40); pyelonephritis (9); and pneumonia (40). Among bacteremic patients receiving shorter (5-7 days) versus longer (7-21 days) antibiotic therapy, no significant difference was detected with respect to rates of clinical cure (45/52 versus 47/49, risk ratio 0.88, 95% confidence interval [CI] 0.77-1.01), microbiologic cure (28/28 versus 30/32, risk ratio 1.05, 95% CI 0.91-1.21), and survival (15/17 versus 26/29, risk ratio 0.97, 95% CI 0.76-1.23). No significant differences in clinical cure, microbiologic cure and survival were detected among bacteremic patients receiving shorter versus longer duration antibiotic therapy. An adequately powered randomized trial of bacteremic patients is needed to confirm these findings.
    Critical care (London, England) 11/2011; 15(6):R267. DOI:10.1186/cc10545 · 4.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intra-abdominal infection management remains debated and evidence-based recommendations are often lacking despite numerous studies. These controversies are mainly explained by the limited number of powered and well designed randomized controlled trials. This review focuses on recent studies on antibiotic therapy for intra-abdominal infections and in particular for the management of severe acute pancreatitis. For community-acquired intra-abdominal infection, early source control and antibiotic selection are well codified. In severe forms, every hour of delay between shock and antibiotherapy initiation reduces hospital survival. Antibiotics dose adjustment and continuous intravenous administration are suggested in critically ill patients and for difficult-to-treat pathogens. Shorter antibiotic treatment duration seems to offer similar clinical cure rates compared with prolonged therapy and could reduce emergence of resistance. For multidrug-resistant bacteria, the newly developed agents indications need to be better defined. In severe acute pancreatitis, antibiotic prophylaxis does not prevent necrosis infection nor does it reduce surgery requirement or mortality. Antibiotics should be given on demand. Infectious complications in pancreatitis are not reduced by probiotic prophylaxis and mortality is increased. There is a growing evidence to support early, dose-adjusted, antimicrobial therapy in severe intra-abdominal infection, together with shorter treatment duration if source control is achieved. This could reduce emergence of resistance without affecting clinical cure rates. In severe acute necrotizing pancreatitis, antibiotic and probiotic prophylaxis to reduce infection or mortality should be avoided.
    Current Opinion in Infectious Diseases 09/2008; 21(4):393-8. DOI:10.1097/QCO.0b013e328306ef2a · 5.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review the new findings on the use of antibiotics in the ICU patients. Although there are several lines of evidence for a prompt use of antibiotics in life-threatening infections, restricting the use of antibiotics should remain the common rule. In order to reduce the emergence of multiresistant bacteria, several approaches have been tested: knowledge of local ecology, choice of the best dose of antibiotics based on their pharmacokinetic and pharmacodynamic properties, de-escalation after results of cultures, and shortening the duration of treatment. An integrative strategy including all these approaches could be associated with a reduced incidence of multiresistant bacteria. Good evidence suggests that a strategy aiming at reducing the prolonged use of broad-spectrum antibiotics is the only mean to reduce the emergence of multiresistant bacteria.
    Current opinion in critical care 11/2008; 14(5):587-92. DOI:10.1097/MCC.0b013e32830f1deb · 2.62 Impact Factor
Show more